Inter‐institutional perspectives on usage of fibrinogen replacement therapies in North America
Vox Sanguinis · 15.09.2026
DOI: 10.1111/vox.70374 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vox Sanguinis, online erschienen am 15.09.2026. Verfasst von Cindy Tay und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Objectives Cryoprecipitated antihemophilic factor (cryoprecipitate), fibrinogen concentrate (FC), and pathogen‐reduced cryoprecipitated fibrinogen complex (PR cryoprecipitate) are sources of fibrinogen replacement, and each has advantages and disadvantages in terms of cost, efficacy, safety, and logistics of administration. This study examines the respective utilization frequencies of these different products at institutions in North America and the factors influencing the decision on which one(s) to adopt. Materials and Methods A survey was distributed via email to contacts for Advancement of Blood and Biotherapies (AABB)‐accredited blood banks/transfusion services. Survey questions covered topics including the availability and usage of FC, cryoprecipitate, and PR cryoprecipitate, as well as the perceived advantages of each product.
Results
A total of 53 responses were received from surveyed institutions (estimated 25% response rate). Over half (31/53, 58.5%) of respondents exclusively used cryoprecipitate, 30.2% (16/53) used two sources of fibrinogen replacement, and 7.5% (4/53) used all three (cryoprecipitate, FC, and PR cryoprecipitate). More than half of the institutions restricted FC to specific indications, primarily for cost containment. The most commonly cited advantages of FC over cryoprecipitate were storage convenience and rapid reconstitution.
Conclusion
Surveyed institutions in the United States and Canada primarily use cryoprecipitate for fibrinogen replacement, with variable usage of FC and limited usage of PR cryoprecipitate. The perception of FC being more expensive than cryoprecipitate predominated. Further studies comparing available fibrinogen replacement options would be valuable, particularly with consideration of product acquisition cost, wastage, impacts on utilization of other blood products, and patient outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Department of Pathology, University of California San Diego, San Diego, California, USA.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
- Department of Pathology and Laboratory Medicine, McGovern Medical School, Houston, Texas, USA.
- Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
ORCID-Profile: Cindy Tay, Laura K Dilly, Wen Lu, Kerry O'Brien, Hlaing Tint, Quentin Eichbaum
Zitieren
APA
Tay, C., Dilly, L. K., Lu, W., O'Brien, K., Tint, H., & Eichbaum, Q. (2026). Inter‐institutional perspectives on usage of fibrinogen replacement therapies in North America. Vox Sanguinis. https://doi.org/10.1111/vox.70374
Vancouver
Tay C, Dilly LK, Lu W, O'Brien K, Tint H, Eichbaum Q. Inter‐institutional perspectives on usage of fibrinogen replacement therapies in North America. Vox Sanguinis. 2026. doi:10.1111/vox.70374
BibTeX
@article{Tay2026,
author = {Tay, Cindy and Dilly, Laura K and Lu, Wen and O'Brien, Kerry and Tint, Hlaing and Eichbaum, Quentin},
title = {Inter‐institutional perspectives on usage of fibrinogen replacement therapies in North America},
journal = {Vox Sanguinis},
year = {2026},
doi = {10.1111/vox.70374}
}
EUVIMED